Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

Fig. 2

First-line overall survival (OS) a across all treatment regimens and b comparing first-line regimens with vs without antiangiogenic therapy (bevacizumab), and first-line progression-free survival (PFS) c across all treatment regimens and d comparing first-line regimens with vs without antiangiogenic therapy (bevacizumab)

Back to article page
\